#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Therapeutic plasma exchange in the treatment of the hereditary thrombotic thrombocytopenic purpura


Authors: Z. Čermáková 1,2;  M. Kořístka 1,3;  B. Kořístková 4;  R. Hrdličková 1;  T. Šuláková 5;  J. Furková 1;  P. Kovářová 1
Authors‘ workplace: Fakultní nemocnice Ostrava, Krevní centrum 1;  Univerzita Karlova v Praze, 1. lékařská fakulta, I. interní klinika VFN 2;  Ostravská univerzita Ostrava, Fakulta zdravotnických studií, Katedra vyšetřovacích metod 3;  Fakultní nemocnice Ostrava, Ústav klinické farmakologie 4;  Fakultní nemocnice Ostrava, Klinika dětského lékařství 5
Published in: Čas. Lék. čes. 2009; 148: 493-496
Category: Original Article

Overview

Therapeutic plasma exchange is the treatment of choice for thrombotic thrombocytopenic purpura (TTP). Patients chronically treated with plasma exchange are frequently exposed to a large number of single plasma donors units, however successfull clinical and laboratory improvement is generally achieved. Therapeutic plasma exchange significantly decreased mortality of this disease. Plasma treatment offers two possibilities – plasma infusion or plasma exchange and possibility of using different plasma types. Cryoprecipitate-poor plasma was introduced as better alternative to FFP, however studies presented later do not confirm the therapeutic benefit. Quarantine FFP is prevalently used for patients with TTP in Czech Republic; this type is tested frequently for negativity of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis. In Czech Republic is not common a treatment with pathogen inactivated plasma: solvent detergent plasma, methylen-blue plasma, psoralen treated plasma or riboflavin treated plasma. Authors are looking for efficacy of different plasma types and present their own experience with plasma treatment in 7 patients with hereditary TTP. In 5 patients therapeutic plasma exchange with quarantine fresh frozen plasma is used. During each treatment 1,5 plasma volume is exchanged. 2 patients – teenagers are treated at the department of pediatrics with plasma infusion in regular 2 weeks intervals.

Key words:
TTP, therapeutic plasma exchange, quarantine fresh frozen plasma

Introduction

Thrombotic thrombocytopenic purpura (TTP) is a serious life-threatening disorder characterized by classic pentad of signs: microangiopatic haemolytic anemia with schistocytes in peripheral blood smear, fever, thrombocytopenia, renal and neurologic dysfunction, nevertheless all these symptoms are fully presented only in a minority of patients (1). ADAMTS 13 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif, repeats13) protease deficiency is responsible for development of the condition. ADAMTS13 cleaves large multimers of von Willebrand factor; in order to prevent the spontaneous formation of platelet thrombi in the microcirculation. The absence or severely reduced plasma ADAMTS13 activity leads to the persistence of high molecular weight vWF multimers with ensuing platelet aggregation and thrombotic microangiopathy (2, 3). There are different presentations of TTP. Congenital TTP is very rare (2 – 3% patients) (4). It is caused by genetic mutations in the coresponding gene. In these patients plasma ADAMTS13 activity could be reduced to the extremely low values (3-5%) while about 10% of protease value is sufficient to multimers cleaving (5, 6). In acquired TTP ADAMTS13 is deficient due to autoantibody inhibitor. Before effective treatment with plasma therapy the outlook of TTP was extremely grave with mortality rates about 90% (7). Plasma exchange or plasma infusions replenish a deficient plasma metalloprotease that cleaves present vWF multimers and in this way induce disease remission. Repeated plasma exchange allows removal of the pathogenic substance and lowering the concentration of specific, tissue-directed antibodies and toxins (8).

Effectiveness of TTP treatment using various plasma products.

Quarantine fresh frozen plasma (FFP)

Quarantine FFP is produced from a single blood donor or is separated from a single donor via machine.  Within six hours is plasma unit (about 250ml) frozen solid in shock freezer at -30°C. Hereby are procoagulation factors preserved. After that plasma is stocked up to 36 months at  -25°C. During first six months of plasma stocking the plasma donors are re-tested for serological markers of HIV, HBV, HCV and syphilis. Screening for these markers are obligatory in Czech republic. This strategy helps to reduce the risk of the pathogen transmission in window period regarding the timing of seroconversion. Quarantine fresh frozen plasma is the most common applicated plasma product in Czech Republic.

Quarantine K-plasma.

Quarantine K-plasma is plasma depleted of cryoprecipitate (cryoprecipitate-poor plasma) prepared in blood establishments. Because of lower fibrinogen, factor VIII, factor XIII and lower large multimers level in K-plasma compared to FFP, it had led to assumption about preferency of K-plasma in TTP treatment (9). Indeed later was approved the significance of metalloprotease level for disease remission that is present in both aforementioned alternatives (10).

Patients with TTP usually require daily plasma exchange in which is replaced 1.0 to 1.5 plasma volumes (3000ml of plasma) with FFP or cryoprecipitate-poor plasma. The therapy continues until the platelet count normalizes and there is minimal hemolysis. Because of the large volume, the number of donor exposures, and prolonged duration of therapy, adverse reactions to plasma are common in the treatment of TTP.  There is a risk of disease transmission, TRALI and allergic complications from mild to serious forms (11,12).

Pathogen inactivated plasmaNowadays pathogen inactivated plasma means solvent-detergent treated plasma, methylen-blue treated plasma, and psoralen or riboflavin treated plasma.

Solvent-detergent treated plasma (SD-plasma)

Solvent-detergent treated plasma is a biopharmaceutical product prepared from pooled FFP (100-1600 donors per batch) with ABO compatibility. Solvent (tri-n-butyl phosphate) -detergent (Triton® X-100) technology inactivates well lipid-enveloped viruses (HIV, HBV, HCV), but is less effective in inactivation of non-enveloped viruses like parvovirus B19 or HAV. Pooling of plasma units can lead to neutralization of antibodies and allergens in plasma and thus significantly decrease risk of TRALI and other serious adverse effects (13). European SD- plasma is predominantly produced by Octapharma (Octapharma, Switzerland) and is distributed as a medical product Octaplas (14). Number of clinical studies confirmed the benefit of Octaplas in treatment of patients with TTP (15,16).

Methylen-blue treated plasma (MB plasma)

Treatment of plasma with methylen blue, a fenothiazin dye, and subsequent visible light exposure generate superoxides (hydrogen peroxide and hydroxyl), which target nucleic acids of the virus (17,18). The System effectively inactivates lipid-enveloped viruses but is less effective in non-lipid enveloped viruses (19). Nevertheless, clinical efficicacy of MB plasma is lower than quarantine FFP (20).

Psoralen inactivated plasma (INTERCEPT)

Riboflavin inactivated plasma (MIRASOL® PRT)

Both systems can be used for pathogen inactivation directly in blood establishments.

INTERCEPT Blood system, produced by Cerus (USA), for plasma uses the addition of a psoralen (amotosalen HCl, S-59) followed by illumination with UVA to inactivate pathogens (21, 22). This system is certificated also for platelets. Until now only one small clinical trial regarding the treatment of TTP was published (23).

MIRASOL® PRT, produced by CaridianBCT, Inc. (USA), treatment utilizes exposure to light in the presence of riboflavin to introduce irreparable lessions to nucleic acids thereby inhibiting pathogen and WBC replication. At present the system is certificated only for platelets treatment. Plasma treatment is still under preclinical development (14).

Patients and results

There are 7 patients with rare congenital TTP are treated in Faculty Hospital Ostrava. Five adult patients undergo regular therapeutical plasma exchange using ComTec 204 separators (Fresenius GmbH, Germany), in intervals (3-7 weeks) derived from empirical experience; it means according to platelet count, which decrease under values that are innate to the patients in the long-term monitoring (the platelet count drop under these values is accompanied by rising level of lactate dehydrogenase). During single plasma exchange 1.5 plasma volumes is replaced with quarantine FFP. Before procedure antihistaminic drugs are administrated, and during the procedure is administrated bolus of corcticosteroids. Even though plasma-related allergic complications were reported. Three patients (no. 1, 2 and 4 see table 1) developed light to mediate allergic reaction as allergic exanthema on upper part of body and respiratory distress. Two of our patients (no. 3 and 6 see table 1) experienced serious generalized allergic reaction. Teenage patients no. 6 and 7 (see table 1) are regularly treated with by plasma infusion (in 2 weeks intervals) in dosage 10ml per kilogram. In one of them was reported serious allergic reaction. 

1. Group of patients with hereditary TTP
Group of patients with hereditary TTP

Discussion

Patients with rare congenital TTP are treated in Faculty Hospital of Ostrava. In all of these patients first symptoms has manifested in childhood; in four of them (1, 3, 5 and 6 see table 1) as relapsing haemolytic – uraemic syndrome. The patient number 2 was primarily diagnosed with idiopathic thrombocytopenic purpura (ITP) at two years of age, The patient number 4 experienced first attack at 13 years of age; the episode was diagnosed as ITP and anemia. Therapeutical plasma exchange is essential in TTP patients (24). Our patients respond to the treatment well, which is apparent from laboratory findings particularly by improvement of thrombocytopenia and parameters of hemolysis (lactate dehydrogenase level). However, plasma replacement has risk. There is as a possibility of pathogen transmission and complications including allergic reactions, volume shifts citrate toxicity and TRALI. However Octaplas is according to the references in foreign literature safer and more efficient. Availability of aforementioned plasma alternatives is challenging. Hence as results of several clinical trials presented the benefit of Octaplas as a substitution solution instead of quarantine FFP, we aim to use this biopharmaceutical product in treatment of selective group of patients with hereditary TTP in future.

Conclusions:

Quarantine fresh frozen plasma is reasonable and effective treatment in the therapy of patients with TTP. Availability of Octaplas, which is as presented in a number of foreign studies more safe and efficient, is in Czech Republic at pressent difficult and due to large volumes of replaced plasma also financial demanding.  

Abbrevations:

ADAMTS13   -          a disintegrin-like and metalloprotease with thrombospondin type 1 motif,  13    

FFP                 -          fresh frozen plasma

HAV               -          hepatitis A virus

HBV                -          hepatitis B virus

HCV               -          hepatitis C virus

HIV                 -          humann immunodeficiency  virus

ITP                  -          idipathic thrombocytopenic purpura

K – plazma      -          cryoprecipitate - poor plasma

MB                  -          methylen blue

PRT                 -         pathogen reduction technology

SD                   -          solvent – detergent

TPE                 -          therapeutic plasma exchange

TRALI             -          transfusion-related acute lung injury

TTP                 -          thrombotic thrombocytopenic purpura

vWF                -          von Willebrand factor


Sources

1. Mannucci P, Peyvandi F. TTP and ADAMTS13: When Testing is Appropriate? Hematology Am Soc Hematol Educ Program 2007; 1: 121–126.

2. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombopenic purpura: N Engl J Med. 1982; 307: 1432–1435.

3. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unussually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456–1461.

4. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, Mc Gee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburd D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488–494.

5. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor – cleaving protease. Best Pract Res Clin Haematol 2001; 14: 437–454.

6. Barbot J, Costa E, Guerra M, et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of congenital deficiency of vonWillenbrand factor-cleaving protease. Br J Haematol 2001; 113: 649–651.

7. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139–159.

8. Rock G. The management of thrombotic thrombocytopenic purpura in 2005. Semin Thromb Hemost 2005; 31: 709–716.

9. Rock G, Shumak KH, Sutton DM, BuskardNA, Nair, RC. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996; 94: 383–386.

10. Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, Bidensteiner D, Silver B, Kramer RE. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). North American TTP GrouP. J Clin Apher 2001; 16: 19–22.

11. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer Ch, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault Ch, CrookstonKP, Benjamin, RJ, George J, Lin JS, Corash L, Conlan MG. A randomized controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46: 1693–1704.

12. Helltern, P. Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma. Transf and Aph J 2008; 39: 69–74.

13. Andreu G. Transfusion-associated circulatory overload and transfusion-related acute lung injury: diagnosis, pathophysiology, management and prevention. Vox Sang 2009; 4: 63–71.

14. Solheim BG, Seghatchan J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transf and Aph Sci 2006; 35: 83–90.

15. Pereira A. Efficacy of different plasma sources in threatment of thrombotic thrombocytopenic purpura. Vox Sang 2009, 4: 111–117. ISBT Science Series (2009).

16. Hellestern P. Haubelt H. Manufacture and composition of fresh frozen plasma and virus inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002; 31: S3–S8.

17. Hellestern P. Solvent/detergent-treated plasma: composition, efficacy and safety. Curr Opin Hematol 2004; 11: 346–350.

18. Chapman J. Virus inactivation of plasma by methylene blue photoinactivation: approaches and toxicology. Transfus Today 1994; 20: 2–4.

19. Mohr H, Lambrecht B, Selz A. Photodynamic virus inactivation of blood components. Immunol Invest 1995; 24: 73–85.

20. Williamson LM, Cardigan R, Prowse Ch. Methylene blue-treated fresh-frozen plasma:what is its contribution to blood safety? Transf 2003; 436: 1322–1329.

21. del Río-Garma J, Alvarez-Larrán A, Martínez C, Muncunill J, Castellá D, de la Rubia J, Zamora C, Corral M, Viejo A, Peňa F, Rodríguez-Vincente P, Contrera, E, Arbona C, Ramírez C, Garcia-Erce J,A, Alegre A, Mateo J, Pereira, A. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic puprura: a multicentric, prospective cohort study. Br J Haematol 2008; 143: 39–45.

22. Janetzko K, Lin L, Eichler H, Mayaudon V, Flamen J, Klüter H. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004; 86: 239–245.

23. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon LI, Lopez-Plaza I, Rouault C, Crooston KP, Benjamin RJ, George J, Lin.JS Corash L, Conlan MG. A randomized, controlled Phase III trial of therapeutic plasma exhange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transf 2006; 46: 1693–1704.

24. Čermáková Z, Hrdličková R, Šuláková T, Kořístka M, Kovářova P, Hrachovinová I. Thrombotic thrombocytopenic purpura: Incidence of congenital form of disease in North Moravia (Region Moravia-Silesia). Prague Medical Report 2009; v tisku.

Labels
Addictology Allergology and clinical immunology Anaesthesiology, Resuscitation and Inten Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric dermatology & STDs Paediatric gastroenterology Paediatric gynaecology Paediatric surgery Paediatric cardiology Paediatric nephrology Paediatric neurology Paediatric clinical oncology Paediatric ENT Paediatric pneumology Paediatric psychiatry Paediatric radiology Paediatric rheumatology Paediatric urologist Diabetology Endocrinology Pharmacy Clinical pharmacology Physiotherapist, university degree Gastroenterology and hepatology Medical genetics Geriatrics Gynaecology and obstetrics Haematology Hygiene and epidemiology Hyperbaric medicine Vascular surgery Chest surgery Plastic surgery Surgery Medical virology Intensive Care Medicine Cardiac surgery Cardiology Clinical speech therapy Clinical microbiology Nephrology Neonatology Neurosurgery Neurology Nuclear medicine Nutritive therapist Obesitology Ophthalmology Clinical oncology Orthodontics Orthopaedics ENT (Otorhinolaryngology) Anatomical pathology Paediatrics Pneumology and ftiseology Burns medicine Medical assessment General practitioner for children and adolescents Orthopaedic prosthetics Clinical psychology Radiodiagnostics Radiotherapy Rehabilitation Reproduction medicine Rheumatology Nurse Sexuology Forensic medical examiner Dental medicine Sports medicine Toxicology Traumatology Trauma surgery Urology Laboratory Home nurse Phoniatrics Pain management Health Care Dental Hygienist Medical student
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#